Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.

Date publication

mai 2019

Journal

Rheumatology (Oxford, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Puéchal X, Pagnoux C, Baron G, Lifermann F, Geffray L, Quémeneur T, Saraux JL, Wislez M, Cottin V, Ruivard M, Limal N, Aouba A, Bonnotte B, Néel A, Agard C, Cohen P, Terrier B, Le Jeunne C, Mouthon L, Ravaud P, Guillevin L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31056661

Résumé

In a previous controlled trial, 1-year adjunction of AZA to glucocorticoids (GC) for patients with non-severe, newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) failed to lower remission failure, vasculitis relapse and isolated asthma/rhinosinus exacerbation rates, or cumulative GC use at month (M) 24. The aim of this study was to analyse longer-term outcomes to determine whether subsequent vasculitis relapse or isolated asthma/rhinosinus exacerbation (IARE) rates differed.

Mots clés

damage, eosinophilic granulomatosis with polyangiitis, glucocorticoids, isolated asthma/rhinosinus exacerbation, vasculitis relapse

Référence

Rheumatology (Oxford). 2019 May 5;: